The most common adverse reactions to Anthrasil observed in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain.
Anthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified. Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and edema toxins. This binding of antibody to PA prevents PA-mediated cellular entry of toxic factors. It is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue to grow and produce anthrax toxins.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Anthrax immune globulin human. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estrone | Estrone may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estradiol | Estradiol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Mestranol | Mestranol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estriol | Estriol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Tibolone | Tibolone may increase the thrombogenic activities of Anthrax immune globulin human. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Anthrax immune globulin human. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Anthrax immune globulin human. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Anthrax immune globulin human. |
| Zeranol | Zeranol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Equol | Equol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Promestriene | Promestriene may increase the thrombogenic activities of Anthrax immune globulin human. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Anthrax immune globulin human. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Anthrax immune globulin human. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Anthrax immune globulin human. |
| Formononetin | Formononetin may increase the thrombogenic activities of Anthrax immune globulin human. |
| Estetrol | Estetrol may increase the thrombogenic activities of Anthrax immune globulin human. |
| Etanercept | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Etanercept. |
| Peginterferon alfa-2a | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Peginterferon alfa-2a. |
| Interferon alfa-n1 | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-n1. |
| Interferon alfa-n3 | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-n3. |
| Peginterferon alfa-2b | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Peginterferon alfa-2b. |
| Anakinra | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Anakinra. |
| Interferon gamma-1b | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon gamma-1b. |
| Interferon alfa-2a | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2a. |
| Aldesleukin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Aldesleukin. |
| Adalimumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Adalimumab. |
| Gemtuzumab ozogamicin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemtuzumab ozogamicin. |
| Pegaspargase | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pegaspargase. |
| Infliximab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Infliximab. |
| Interferon beta-1b | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon beta-1b. |
| Interferon alfacon-1 | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfacon-1. |
| Trastuzumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trastuzumab. |
| Rituximab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Rituximab. |
| Basiliximab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Basiliximab. |
| Muromonab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Muromonab. |
| Ibritumomab tiuxetan | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Ibritumomab tiuxetan. |
| Tositumomab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tositumomab. |
| Alemtuzumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alemtuzumab. |
| Cyclosporine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclosporine. |
| Alefacept | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Alefacept. |
| Efalizumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Interferon alfa-2b. |
| Natalizumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Natalizumab. |
| Daclizumab | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Daclizumab. |
| Phenylalanine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Phenylalanine. |
| Bortezomib | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bortezomib. |
| Cladribine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cladribine. |
| Carmustine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carmustine. |
| Amsacrine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Amsacrine. |
| Bleomycin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bleomycin. |
| Chlorambucil | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Chlorambucil. |
| Raltitrexed | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Raltitrexed. |
| Mitomycin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mitomycin. |
| Bexarotene | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bexarotene. |
| Vindesine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vindesine. |
| Floxuridine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Floxuridine. |
| Indomethacin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Indomethacin. |
| Tioguanine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Tioguanine. |
| Vinorelbine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vinorelbine. |
| Dexrazoxane | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dexrazoxane. |
| Sorafenib | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sorafenib. |
| Streptozocin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Streptozocin. |
| Trifluridine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Trifluridine. |
| Gemcitabine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Gemcitabine. |
| Teniposide | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Teniposide. |
| Epirubicin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Epirubicin. |
| Chloramphenicol | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Chloramphenicol. |
| Lenalidomide | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Lenalidomide. |
| Altretamine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Altretamine. |
| Zidovudine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Zidovudine. |
| Cisplatin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cisplatin. |
| Oxaliplatin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Oxaliplatin. |
| Cyclophosphamide | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Cyclophosphamide. |
| Vincristine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vincristine. |
| Fluorouracil | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fluorouracil. |
| Propylthiouracil | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Propylthiouracil. |
| Pentostatin | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pentostatin. |
| Methotrexate | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Methotrexate. |
| Carbamazepine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Carbamazepine. |
| Vinblastine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Vinblastine. |
| Linezolid | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Linezolid. |
| Imatinib | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Imatinib. |
| Clofarabine | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Clofarabine. |
| Pemetrexed | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Pemetrexed. |
| Mycophenolate mofetil | The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Mycophenolate mofetil. |